Search results
Benzene Exposure Linked to Acute Myeloid Leukemia, Aplastic Anemia, and Lymphomas | JD Supra
JD Supra· 4 days agoIf you have been diagnosed with acute myeloid leukemia but cannot figure out why, benzene may be responsible. Benzene, a chemical used ...
Patients Over 80 Still Benefit From Treatment for AML Blood Cancer
Alaska Superstation· 7 days agoSeniors over 80 with acute myeloid leukemia can safely and effectively take the standard targeted...
Earnings call: Aptose Biosciences targets AML treatment with tuspetinib By Investing.com
Investing.com· 6 days agoAptose Biosciences (NASDAQ:APTO) has focused its efforts on developing tuspetinib as part of a novel...
Ryvu Therapeutics First Quarter 2024 Financial Results and Corporate Update
FOX 59 Indianapolis· 6 days agoAs of May 9, 2024, Ryvu's cash position was $59.0M, inclusive of the first tranche of €8M in venture...
Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients...
WTNH-TV New Haven· 6 days agoThe Phase 3 SIERRA trial enrolled 153 patients ages 55 and above with active relapsed or refractory acute myeloid leukemia (r/r AML) ...
Curis reports progress in leukemia study with expanded patient dataset By Investing.com
Investing.com· 6 days agoCuris, Inc. (NASDAQ: CRIS), a biotechnology company, has announced an expansion of its dataset in an...
Bio-Path Holdings Inc (BPTH) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ...
GuruFocus.com via Yahoo Finance· 5 days agoPositive Points Bio-Path Holdings Inc (NASDAQ:BPTH) reported positive interim results from Stage 2 of the Phase 2 clinical trial of prexigebersen for treating acute
Anti-diabetic treatment associated with reduced risk of developing blood cancer
Medical Xpress· 4 days agoMetformin is a therapy used to treat high blood sugar in people with type 2 diabetes that increases...
Ryvu Therapeutics to present clinical and preclinical data on RVU120 at the 2024 European Hematology...
FOX 23 News Albany· 7 days agoUpdated data from the Phase I trial of RVU120 in patients with relapsed/refractory acute myeloid ...
Newswise Expert | Namrata Chandhok, University of Miami Health System, Miller School of Medicine
Newswise· 9 hours agoNamrata Chandhok, M.D. is an Assistant Professor of Clinical Medicine (Hematology) at the University of Miami Miller School of Medicine/ Sylvester Comprehensive Cancer Center. Dr. Chandhok specializes ...